薬学部
教員紹介
![[写真]](/images/shared/teacher/pht_teacher516_s.jpg)
| 氏名 | 市丸 嘉 |
|---|---|
| フリガナ（ローマ字） | イチマル ヨシミ（Yoshimi Ichimaru） |
| 職名 | 講師 |
| 学位 | 博士（薬学） |
| 担当授業科目 | 早期臨床体験実習、化学系実習、医療薬学チュートリアル演習Ⅰ、有機化学実習、薬学総合プレ研究、後期臨床体験実習、医療薬学チュートリアル演習Ⅱ、薬局実務実習、卒業研究Ⅰ、卒業研究Ⅱ、総合演習Ⅰ |
| 専門分野 | 薬化学，分析化学，生物有機化学 |
| 現在の研究テーマ | インディルビン誘導体の抗がん活性，X線結晶構造解析，クオラムセンシングを標的とした創薬 |
| 研究内容キーワード | インディルビン，金属錯体，X線結晶構造解析，オートインデューサー |
| 研究室紹介 | 薬化学 |
| ティーチング・ ポートフォリオ |
|
| 主な著書・学術論文 | Characterization of Zinc(II) Complex of 1,4,7,10-Tetrazacyclododecane and Deprotonated 5-Fluorouracil (FU) in Crystalline/Solution States and Evaluation of Anticancer Activity: Approach for Improving the Anticancer Activity of FU: Y. Ichimaru, K. Kato, R. Nakatani, K. Sugiura, H. Mizutani, E. Kinoshita-Kikuta, T. Koike, W. Jin, M. Imai, and H. Kurosaki. Inorganic Chemistry Communications (2022)147;110221. |
| Bis(nitrato-κO)(1,4,8,11-tetraazacyclotetradecane-κ4N)zinc(II) methan: Y. Ichimaru, K. Kato, M. Kurihara, W. Jin, T. Koike, and H. Kurosaki. IUCrData (2022)7;x220854. | |
| Crystal Structure of [{m,m-bis(ZnII-cyclen)}3(μ2-CO3)2(H2O)2](ClO4)8·nH2O: Y. Ichimaru, K. Kato, K. Sugiura, C. Hirata, W. Jin, H. Fujioka, H. Kurosaki, and T. Koike. X-ray Structure Analysis Online (2022)38;53. | |
| Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma : Y. Oshima, M. Sano, I. Kajiwara, Y. Ichimaru, T. Itaya, T. Kuramochi, E. Hayashi, J. Kim, O. Kitajima, Y. Masugi, A. Masamune, H. Ijichi, Y. Ishii, and T. Suzuki. British Journal of Anaesthesia (2022)128;679. | |
| Crystal Structure of Bis{1,3-bis[bis(pyridin-2-ylmethyl)amino]propan-2-olato-dizinc(II)}orthophosphate Tris(perchlorate) Octahydrate, [(Phos-tag)2-PO43−][ClO4−]3·8H2O: Y. Ichimaru, K. Kato, W. Jin. K. Sugiura, E. Kinoshita-Kikuta, E. Kinoshita, H. Kurosaki, and T. Koike. X-ray Structure Analysis Online (2021)37;87. | |
| Characterization of the Binding of Adenosine-5′-monophosphate to a µ-Type Alkoxide-Linked Dinuclear Zinc(II) Complex in Crystal and Solution State: E. Kinoshita-Kikuta, Y. Ichimaru, Y. Yamano, K. Kato, H. Kurosaki, E. Kinoshita, and T. Koike. Bulletin of the Chemical Society of Japan (2021)94;2670. | |
| Crystal Structures of Metallo-β-Lactamase (IMP-1) and Its D120E Mutant in Complexes with Citrate and the Inhibitory Effect of the Benzyl Group in Citrate Monobenzyl Ester: Y. Yamaguchi, K. Kato, Y. Ichimaru, W. Jin, M. Sakai, M. Abe, J. Wachino, Y. Arakawa, Y. Miyagi, M. Imai, N. Fukuishi, Y. Yamagata, M. Otsuka, M. Fujita, and H. Kurosaki. Journal of Medicinal Chemistry (2021)64;10019. | |
| Aqua(1,4,7,10-tetraazacyclododecane)zinc(II) bis(perchlorate): Y. Ichimaru, K. Kato, H Kurosaki, H. Fujioka, M. Sakai, Y. Yamaguchi, J. Wanchun, K. Sugiura, M. Imai, and T. Koike. IUCrData (2021)6;x210397. | |
| Crystal Structure of [11,14,17,110,51,54,57,510-Octaaza-1,5(1,4)-dicyclododecana-3,7(1,3)-dibenzenacyclooctaphane]zinc(II) tetrakis(nitrate), [m,m-bis(ZnII-cyclen)](NO3)4: Y. Ichimaru, W. Jin, Y. Yamaguchi, K. Sugiura, M. Imai, H. Kurosaki, H. Fujioka, T. Koike, Y. Hieda, and K. Kato. X-ray Structure Analysis Online (2021)37;15. | |
| Design and synthesis of an anthranyl bridged optically active dinuclear iron(II)-ligand and evaluation of DNA-cleaving activity: Y. Ichimaru, K. Kato, Y. Okuno, Y. Yamaguchi, W. Jin, M. Fujita, M. Otsuka, M. Imai, and H. Kurosaki. Bioorganic & Medicinal Chemistry Letters (2021)35;127782. | |
| Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects: I. Kajiwara, M. Sano, Y. Ichimaru, Y. Oshima, O. Kitajima, H. Hao, A. Masamune, J. Kim, Y. Ishii, H. Ijichi, and T. Suzuki. Pain(2020)161; 2909. | |
| Crystal Structure of [3-(1,4,7,10-Tetraazacyclododecan-1-yl)propan-1-amine]zinc(II) Bis(perchlorate), [ZnIIL](ClO4)2: Y. Ichimaru, M. Imai, H. Fujioka, Y. Hieda, T. Koike, H. Kurosaki, and K. Kato. X-ray Structure Analysis Online (2020)36;43. | |
| Sasa veitchii extract induces anticancer effects via inhibition of cyclin D1 expression in MCF-7 cells: Y. Ichimaru, N. Kanaeda, S. Tominaga, M. Suzui, T. Maeda, H. Fujii, M. Nakao, and H. Yoshioka. Nagoya Journal of Medical Science (2020)82;509. | |
| Indirubin 3'-oxime inhibits migration, invasion, and metastasis In vivo in mice bearing spontaneously occurring pancreatic cancer via blocking the RAF/ERK, AKT, and SAPK/JNK pathways: Y. Ichimaru, M. Sano, I. Kajiwara, T. Tobe, H. Yoshioka, K. Hayashi, H. Ijichi, and S. Miyairi. Translational Oncology (2019)12;1574. | |
| 5-Bromoindirubin 3 '-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase: Y. Ichimaru, T. Fujii, H. Saito, M. Sano, T. Uchiyama, and S. Miyairi. Bioorganic & Medicinal Chemistry (2017)25;4665. | |
| Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo: M. Sano, Y. Ichimaru, M. Kurita, E. Hayashi, T. Homma, H. Saito, S. Masuda, N. Nemoto, A. Hemmi, T. Suzuki, S. Miyairi, and H. Hao. Cancer Letters(2017)397;72. | |
| Indirubin 3 '-(O-oxiran-2-ylmethyl)oxime: A novel anticancer agent: Y. Ichimaru, H. Saito, T. Uchiyama, K. Metori, K. Tabata, T. Suzuki, and S. Miyairi. Bioorganic & Medicinal Chemistry Letters (2015)25;1403. |